JP2021522280A5 - - Google Patents

Info

Publication number
JP2021522280A5
JP2021522280A5 JP2020560361A JP2020560361A JP2021522280A5 JP 2021522280 A5 JP2021522280 A5 JP 2021522280A5 JP 2020560361 A JP2020560361 A JP 2020560361A JP 2020560361 A JP2020560361 A JP 2020560361A JP 2021522280 A5 JP2021522280 A5 JP 2021522280A5
Authority
JP
Japan
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020560361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522280A (ja
JP7489323B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030068 external-priority patent/WO2019213174A1/en
Publication of JP2021522280A publication Critical patent/JP2021522280A/ja
Publication of JP2021522280A5 publication Critical patent/JP2021522280A5/ja
Priority to JP2024078186A priority Critical patent/JP2024112864A/ja
Application granted granted Critical
Publication of JP7489323B2 publication Critical patent/JP7489323B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560361A 2018-04-30 2019-04-30 Cd73阻害剤 Active JP7489323B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024078186A JP2024112864A (ja) 2018-04-30 2024-05-13 Cd73阻害剤

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862664841P 2018-04-30 2018-04-30
US62/664,841 2018-04-30
US201862737647P 2018-09-27 2018-09-27
US62/737,647 2018-09-27
US201862757714P 2018-11-08 2018-11-08
US62/757,714 2018-11-08
US201862777697P 2018-12-10 2018-12-10
US62/777,697 2018-12-10
US201962810790P 2019-02-26 2019-02-26
US62/810,790 2019-02-26
PCT/US2019/030068 WO2019213174A1 (en) 2018-04-30 2019-04-30 Cd73 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024078186A Division JP2024112864A (ja) 2018-04-30 2024-05-13 Cd73阻害剤

Publications (3)

Publication Number Publication Date
JP2021522280A JP2021522280A (ja) 2021-08-30
JP2021522280A5 true JP2021522280A5 (enExample) 2022-04-26
JP7489323B2 JP7489323B2 (ja) 2024-05-23

Family

ID=68386646

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560361A Active JP7489323B2 (ja) 2018-04-30 2019-04-30 Cd73阻害剤
JP2024078186A Pending JP2024112864A (ja) 2018-04-30 2024-05-13 Cd73阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024078186A Pending JP2024112864A (ja) 2018-04-30 2024-05-13 Cd73阻害剤

Country Status (13)

Country Link
US (4) US11325938B2 (enExample)
EP (2) EP3787635B1 (enExample)
JP (2) JP7489323B2 (enExample)
KR (1) KR20210018255A (enExample)
CN (2) CN112423764A (enExample)
AU (1) AU2019261976B2 (enExample)
BR (1) BR112020022068A2 (enExample)
CA (1) CA3098493A1 (enExample)
IL (1) IL304348B2 (enExample)
MX (2) MX2020011542A (enExample)
SG (1) SG11202010790XA (enExample)
TW (1) TW202014182A (enExample)
WO (1) WO2019213174A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
WO2019090111A1 (en) * 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
CN112423764A (zh) 2018-04-30 2021-02-26 欧瑞克制药公司 Cd73抑制剂
WO2019232319A1 (en) * 2018-05-31 2019-12-05 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
MX2020013320A (es) 2018-06-21 2021-02-22 Calithera Biosciences Inc Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
CA3134613A1 (en) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5
EP3999517A4 (en) 2019-07-16 2023-07-12 Oric Pharmaceuticals, Inc. CD73 INHIBITORS
IL292570B2 (en) 2019-10-30 2024-04-01 Oric Pharmaceuticals Inc Cd73 inhibitors
AU2021389685A1 (en) * 2020-11-25 2023-07-06 Risen (Suzhou) Pharma Tech Co., Ltd. Cd73 inhibitors and pharmaceutical uses thereof
TW202308657A (zh) 2021-05-11 2023-03-01 大陸商四川海思科製藥有限公司 小分子cd73拮抗劑及其用途
US20240140979A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
WO2024076873A1 (en) * 2022-10-03 2024-04-11 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
CN116217644B (zh) * 2023-04-24 2023-08-08 南京颐媛生物医学研究院有限公司 抗冠状病毒核糖核苷类化合物及其制备方法和应用
WO2025162964A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of endometriosis
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477454A1 (en) * 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
AU2002232660A1 (en) 2000-12-15 2002-06-24 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
US20040229839A1 (en) * 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
EP3134411B1 (en) * 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
WO2017098421A1 (en) * 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
SG11201805506YA (en) 2016-01-08 2018-07-30 Arcus Biosciences Inc Modulators of 5'-nucleotidase, ecto and the use thereof
TWI767937B (zh) 2016-09-09 2022-06-21 美商卡利泰拉生物科技公司 外核苷酸酶抑制劑及其使用方法
EP3518934A4 (en) 2016-10-03 2020-06-24 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
JP7150712B2 (ja) 2016-11-18 2022-10-11 アーカス バイオサイエンシズ インコーポレイティド Cd73媒介免疫抑制の阻害剤
CA3047988A1 (en) 2016-12-22 2018-06-28 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
US20200115404A1 (en) 2017-03-31 2020-04-16 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018208727A1 (en) 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
WO2019090111A1 (en) * 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
CN112423764A (zh) 2018-04-30 2021-02-26 欧瑞克制药公司 Cd73抑制剂
WO2019232319A1 (en) 2018-05-31 2019-12-05 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
MX2020013320A (es) 2018-06-21 2021-02-22 Calithera Biosciences Inc Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
WO2020046813A1 (en) 2018-08-27 2020-03-05 Arcus Biosciences, Inc. Cd73 inhibitors
CA3143496A1 (en) 2019-06-20 2020-12-24 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
EP3999517A4 (en) 2019-07-16 2023-07-12 Oric Pharmaceuticals, Inc. CD73 INHIBITORS
IL292570B2 (en) 2019-10-30 2024-04-01 Oric Pharmaceuticals Inc Cd73 inhibitors

Similar Documents

Publication Publication Date Title
JP2024520481A5 (enExample)
JP2021527638A5 (enExample)
JP2012526728A5 (enExample)
JP2024100974A5 (enExample)
JP2017536395A5 (enExample)
JP2017512833A5 (enExample)
JP2021513534A5 (enExample)
JP2024541910A5 (enExample)
JP2024539946A5 (enExample)
JP2020530487A5 (enExample)
JP2020531422A5 (enExample)
JP2014511876A5 (enExample)
JP2018533593A5 (enExample)
JP2017523169A5 (enExample)
JP2021523200A5 (enExample)
JP2018529650A5 (enExample)
JP2017508816A5 (enExample)
JP2023553835A5 (enExample)
JP2015537008A5 (enExample)
RU2017121906A (ru) Конъюгаты цистеамина и жирной кислоты и их применение в качестве активаторов аутофагии
JP2018537413A5 (ja) 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
JP2020535124A5 (enExample)
JP2016530259A5 (enExample)
JP2019518766A5 (enExample)
JP2017524025A5 (enExample)